Objective: Parents of young children with type 1 diabetes report developmental and management challenges and diabetes-related distress. In the SENCE trial with children 2-<8 yrs, we described improved parental psychosocial outcomes from baseline to 26 wks when continuous glucose monitoring (CGM) was combined with a family behavioral intervention (FBI), compared to CGM alone and to standard blood glucose monitoring. We now explore psychosocial outcomes in the CGM+FBI and CGM alone groups over the extension phase (observation without intervention, 26 to 52 wks post-baseline).
Method: Parents (N=143, children: 50% female, 68% non-Hispanic White, age=5.7±1.8 yrs, A1c=8.2±0.8%) completed validated surveys of diabetes burden, diabetes family impact, hypoglycemia fear, and treatment regimen impact at baseline, 26, and 52 wks. We analyzed 52 week outcomes using within-group t tests and between-group longitudinal models.
Results: Survey scores were stable from 26 to 52 wks, although differences from baseline to 52 wks were not significant (p<.01) (Table).
Conclusion: Introducing CGM with FBI improves parental psychosocial outcomes for at least 6 mos; the similar results at 12 mos suggest durability to 1 yr. Importantly, adding CGM to diabetes regimens in young children, especially with behavioral support, does not appear to add to parents’ perceived burden or fear of low blood glucose.
M.E. Hilliard: None. L. Kanapka: None. L.M. Laffel: Advisory Panel; Self; Roche Diabetes Care. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., ConvaTec Inc., Dexcom, Inc., Insulet Corporation, Insulogic LLC, Janssen Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk Inc., Sanofi US. B. Anderson: None. K. Miller: None. W. Levy: None. M.A. Van Name: None. P.V. Commissariat: None. L. DiMeglio: None.
The Leona M. and Harry B. Helmsley Charitable Trust